期刊
FRONTIERS IN MOLECULAR NEUROSCIENCE
卷 4, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fnmol.2011.00024
关键词
GSK-3; kinases modulation; tau pathologies; Alzheimer
资金
- CDTI's CENIT program [CEN-20101023]
- Ministerio de Ciencia y Tecnologia [SAF2009-12249-C02-02]
- CDTI program CLNIT-INGENIO:Consorcio MELIUS
- CDTI program CLNIT-INGENIO:Consorcio MIND [050106090004]
- MICIN [SAF2009-12249-C02-01]
- EU-FP7 [CT222887, 223276]
- CIBERNED
- Fundacion Areces
Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells. In mammals, at least three proteins (alpha, beta 1, and beta 2), generated from two different genes, gsk-3 alpha and gsk-3 beta, are widely expressed at both the RNA and protein levels although some tissues show preferential expression of some of the three proteins. Control of GSK-3 activity occurs by complex mechanisms that depend on specific signaling pathways, often controlling the inhibition of the kinase activity. GSK-3 appears to integrate different signaling pathways from a wide selection of cellular stimuli. The unique position of GSK-3 in modulating the function of a diverse series of proteins and its association with a wide variety of human disorders has attracted significant attention as a therapeutic target and as a means to understand the molecular basis of brain disorders. Different neurodegenerative diseases including frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's disease, present prominent tau pathology such as tau hyperphosphorylation and aggregation and are collectively referred to as tauopathies. GSK-3 has also been associated to different neuropsychiatric disorders, like schizophrenia and bipolar disorder. GSK-3 beta is the major kinase to phosphorylate tau both in vitro and in vivo and has been proposed as a target for therapeutic intervention. The first therapeutic strategy to modulate GSK-3 activity was the direct inhibition of its kinase activity. This review will focus on the signaling pathways involved in the control of GSK-3 activity and its pathological deregulation. We will highlight different alternatives of GSK-3 modulation including the direct pharmacological inhibition as compared to the modulation by upstream regulators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据